Description |
BGC20-761 is a selecvtive 5-HT6 and dopamine receptor antagonist (human receptor Ki values: 5-HT6 (20 nM), 5-HT2A (69 nM), D2 (140 nM). BGC20-761, can enhance long-term memory. BGC20-761 has potential utility as an antipsychotic agent[1].
|
Related Catalog |
|
Target |
Human 5-HT6 Receptor:20 nM (Ki)
Human 5-HT2A Receptor:69 nM (Ki)
Human D2 Receptor:140 nM (Ki)
|
In Vitro |
BGC20-761 has highly potent and selective 5-HT6 receptor antagonist activity; rat Ki values for other rats receptors: 5-HT2A (470 nM), 5-HT2C (675 nM), D2, D3, D4, DAT and SERT (>10,000 nM)[1].
|
In Vivo |
BGC20-761 enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism. BGC20-761 (2.5 mg/kg, 5 mg/kg and 10 mg/kg; i.p.) alone has no effect on social recognition in young rats, however, at doses of 5 mg/kg and 10 mg/kg i.p, BGC20-761 dose-dependently reverses a deficit of social recognition induced by Scopolamine (0.4 mg/kg i.p.)[1]. Animal Model: Forty-two male 8-week-old Longe Evans rats and 12 male four-week-old SpragueeDawley rats[1] Dosage: 2.5 mg/kg, 5 mg/kg and 10 mg/kg Administration: Administered (i.p.) immediately after the training session for the social recognition test Result: Administered alone did not show any difference in social recognition as compared to saline treated control animals. However, 5 mg/kg and 10 mg/kg reversed a Scopolamine induced deficit in social recognition.
|
References |
[1]. Ellen S Mitchell, et al. BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism. Neuropharmacology. 2006 Mar;50(4):412-20.
|